Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche 2020 results
Roche 2020 results Basel, 4 February 2021
Slide 4: Group
Group Severin Schwan Chief Executive Officer
Slide 5: 2020 performance, Outlook
2020 performance Outlook 5
Slide 6: 2020: Targets fully achieved despite COVID-19 pandemic
2020: Targets fully achieved despite COVID-19 pandemic Targets for 2020 FY 2020 Group sales growth1 Low- to mid-single digit +1% Core EPS growth1 Broadly in line with sales growth +4% Dividend outlook Further increase dividend in Swiss francs2 CHF 9.10 1 At constant exchange rates (CER); 2 2020 divi
Slide 7: 2020: Successfully managing the transition in volatile environment
2020: Successfully managing the transition in volatile environment Compensated for biosimilar & COVID-19 Efficiency gains & investment into future Group Group Sales Core OP CHFm (CER) + 4,739 CHFm (CER) - 5,051 2 + 981 + 1,812 + 1,800 - 40 -868 - 803 - 5,919 23,460 23,460 61,396 62,015 - 968 22,478
Slide 8: Responding quickly and broadly to the pandemic
Responding quickly and broadly to the pandemic Collaboration with Atea on AT-527 development of AT-527 Pharma Collaboration with Regeneron on FDA EUA granted in mild- casirivimab/imdevimab casirivimab/imdevimab global supply moderate adults and adolescents COVACTA trial REMDACTA trial COVACTA EMPACT
Slide 9: Potential use cases for COVID-19 portfolio
Potential use cases for COVID-19 portfolio Pre-exposure/asymptomatic Symptomatic Post-vaccination (screening and prophylaxis) (diagnosis and treatment) (to confirm protection) PCR Use cases will continue to Antigen test persist with vaccine rollout Diagnostics IL-6 test • People not yet vaccinated •
Slide 10: 2020: Sales growth due to Diagnostics Division
2020: Sales growth due to Diagnostics Division 2020 2019 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 44.5 48.5 -8 -2 Diagnostics Division 13.8 12.9 6 14 Roche Group 58.3 61.5 -5 1 CER=Constant Exchange Rates 10
Slide 11: 2020: Group sales growth impacted by COVID-19
2020: Group sales growth impacted by COVID-19 16% 14% 13% 12% 10% 9% 9% 8% 8% 7% 7% 7%7% 7% 6% 6%6% 6% 6% 6% 6% 6% 8% 6% 6% 6% 5% 4% 5% 5% 5% 4% 2% 4% 4% 4% 4% 4% 1% 1% 3% 3% 2% 0% -2% -4% -4% -6% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q
Slide 12: 2020: Pandemic heavily impacting business dynamics
2020: Pandemic heavily impacting business dynamics % CER 1st wave 2nd wave +60% +50% Pharmaceuticals +50% • Severe impact from biosimilars and COVID-19 +40% +32% • Q4 carry over effect (Ocrevus administration) +30% +25% +28% +20% +18% +24% Diagnostics +10% +7% +2% • Routine diagnostics impacted by C
Slide 13: Pharma: New products with strong momentum
Pharma: New products with strong momentum Accelerated portfolio rejuvenation in Q4 2020 Pharma sales mix CHFm % of Pharma Sales 2019 21,000 41% 18,000 40% 31% 31% 15,000 29% 12,000 22% 9,000 2020 15% 6,000 29% 41% 3,000 0 30% FY 2017 FY 2018 FY 2019 FY 2020 Erivedge Perjeta Kadcyla Gazyva New produc
Slide 14: 2020: Growth of profitability and Core EPS
2020: Growth of profitability and Core EPS Core operating profit Core EPS Operating free cash flow 36.9% 33.0% 34.0% 36.1% 36.6% % of sales +1.2%p1 25.4% -7.5%p1 +4% at 1CER +4% -21% 1 CHFbn CHF +4% +4% at 1CER CHFbn -21% at CER 21.5 22.5 19.16 20.16 20.9 20.5 18.14 18.7 14.8 2018 2019 2020 2018 201
Slide 15: 2020 performance, Outlook
2020 performance Outlook 15
Slide 16: Continuing to invest in innovation
Continuing to invest in innovation Assets in Ph III & registration at all time high Diagnostics major systems launches ahead 221 cobas® 58002 cobas® pure2 19 2 2 6 14 13 5 2 2 3 10 2 5 3 2 5 4 cobas® pro (high throughput) 1 1 1 1 1 1 8 8 NMEs 5 4 4 FY 2017 FY 2018 FY 2019 FY 2020 Outlook FY 2021 NME
Slide 17: Strong short- and mid-term news flow
Strong short- and mid-term news flow Diversifying the late stage pipeline and setting new standards of care Product Indication Filing/Data Product Indication Filing/Data tominersen Huntington’s 2022 Adj SCCHN 2021 gantenerumab Alzheimer’s 2022 (Neo)Adj NSCLC 2021/22 Tecentriq SRP-9001 DMD latest 202
Slide 18: Outlook 2021: Growing sales & profit and investing in the future
Outlook 2021: Growing sales & profit and investing in the future Aim to defend margins despite headwinds Sales1 Expenses Pharma: New Products growth to continue overcompensating for the biosimilar impact Diagnostics: Strong sales growth expected in particular in H1 21 Pharma: AHR erosion additional
Slide 19: 2021 outlook: Further growing top and bottom line
2021 outlook Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID-19 impact
Slide 20: Pharmaceuticals Division
Pharmaceuticals Division Bill Anderson CEO Roche Pharmaceuticals
Slide 21: 2020: Pharmaceuticals Division sales
2020: Pharmaceuticals Division sales New products growing strongly – sales impacted by COVID-19 pandemic 2020 2019 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 44,532 48,516 -8 -2 United States 23,647 26,711 -11 -6 Europe 8,198 8,453 -3 1 Japan 3,765 4,143 -9 -6 International 8,922 9,209 -
Slide 22: 2020: Pharma Division core operating profit
2020: Pharma Division Core operating profit stable vs. prior year and significant reallocation of resources into R&D 2020 2020 vs. 2019 CHFm % sales CER growth Sales 44,532 100 -2% Royalties & other op. inc. 1,959 4.4 -7% Cost of sales -8,070 -18.2 -16% M&D -6,633 -14.9 -8% R&D -10,597 -23.8 8% G&A
Slide 23: Reallocating resources into R&D
Reallocating resources into R&D Providing more patient benefit at less cost to society launched NMEs in clinical development * #12 #1 #19 undisclosed #15 #8 #7 #6 #2 #1 1 First approval of a new molecule in a new indication; * Molecule classification for NMEs in clinical development where details ha
Slide 24: 2020: Strong growth for new products
2020: Strong growth for new products leading to a more diversified portfolio Tecentriq 55% Hemlibra 68% Ocrevus 24% Actemra / RoActemra 32% Perjeta 18% Kadcyla 34% Alecensa 40% Polivy 248% Gazyva 21% TNKase / Activase 5% Evrysdi n/a Xolair 2% Esbriet 4% Xofluza 370% Phesgo n/a Enspryng n/a Lucentis
Slide 25: New products account for >47% of Pharma sales
New products account for >47% of Pharma sales* 4 NMEs launched in 2020: ENSPRYNG, PHESGO, GAVRETO & EVRYSDI CHFm % of Pharma Sales* 5,000 47% 4,500 35% 4,000 3,500 3,000 24% 2,500 2,000 17% 1,500 1,000 500 0 Q4 17 Q4 18 Q4 19 Q4 20 Erivedge Perjeta Kadcyla Gazyva Esbriet Cotellic Alecensa Tecentriq
Slide 26: 2020: Oncology -10% due to biosimilars & COVID-19
2020: Oncology -10% due to biosimilars & COVID-19 YoY CER growth HER2 franchise • Kadcyla and Perjeta with strong global uptake in adjuvant BC • Phesgo launched in US and EU Avastin franchise • Biosimilar erosion in all regions Hematology franchise* • Venclexta: Strong growth in 1L CLL and 1L AML •
Slide 27: Hematology franchise: Growth from Venclexta, Gazyva, and Polivy
Hematology franchise: Growth from Venclexta, Gazyva, and Polivy Hematology franchise Q4 update CHFm YoY CER growth CD20 franchise 2,000 • MabThera/Rituxan onc (-43%): Biosimilar and COVID-19 impact • Gazyva (+6%): Growth in 1L CLL and 1L FL; some COVID-19 impact -3% 1,500 -8% +3% Venclexta* • Strong
Slide 28: Hematology franchise: CD20 x CD3 program update
Hematology franchise: CD20 x CD3 program update Potential for early filings in 3L+ FL and 3L+ DLBCL Ph I (GO29781): Mosunetuzumab in R/R FL Ph I (NP30179): Glofitamab in R/R DLBCL High responsebest Investigator-assessed rates in heavily objective pre-treated DLBCL response High response rates in hig
Slide 29: Tecentriq overview: Growth driven by first-in-class indications
Tecentriq overview: Growth driven by first-in-class indications First adjuvant trials to read out in 2021 Tecentriq Q4 update CHFm YoY CER growth Lung franchise (NSCLC, SCLC) 800 • US/EU/Japan: Growth driven by 1L SCLC and 1L NSCLC +49% +35% 700 +99% +54% • BTD for tiragolumab + Tecentriq in PDL1+ N
Slide 30: Lung cancer franchise: Alecensa in ALK+ NSCLC
Lung cancer franchise: Alecensa in ALK+ NSCLC Strong 1L momentum continues in all markets CHFm YoY CER growth Alecensa Q4 update 350 +54% • US (-4%): 1L New patient share > 70% 300 • EU (+22%): 1L New patient share EU-5 >80% 250 +11% +69% • Japan (+29%): 1L New patient share > 70% 200 • Internationa
Slide 31: Hemophilia A franchise: Hemlibra growing strongly
Hemophilia A franchise: Hemlibra growing strongly 28% total US patient share and 22% total EU-5 patient share reached CHFm YoY CER growth 700 Hemophilia Q4 update +45% 600 +57% • US/EU: Gaining market share in non-inhibitors +146% +59% 500 +313% • Minor COVID-19 impact leading to delayed patient sta
Slide 32: Immunology franchise: Stable sales driven by Actemra
Immunology franchise: Stable sales driven by Actemra CHFm YoY CER growth Immunology Q4 update 2,500 Esbriet (-9%) +12% 0% • Growth in mild/moderate segments +10% +2% • BTD in unclassifiable interstitial lung disease (uILD) 2,000 Actemra (+29%) 1,500 • Remains leading RA monotherapy in EU-5 • Sales d
Slide 33: MS franchise: Ocrevus with 25% total US market share
MS franchise: Ocrevus with 25% total US market share Market leadership momentum continues Ocrevus Q4 update CHFm YoY CER growth • US new patient share remains ~40% 1,500 • Q4 growth despite COVID-19 and carry over from Q2 (1st wave) 1,250 +37% • Shorter infusion approved in US +38% +55% +10% • Highe
Slide 34: SMA franchise: Successful virtual US launch of Evrysdi
SMA franchise: Successful virtual US launch of Evrysdi >1,000 US patients treated (>10% total share) after less than 5 months Broad uptake across all patient types Access enabled by compelling value proposition Patients treated with all SMA types Pattern mirrors disease prevalence: • ~55% of lives c
Slide 35: Ophthalmology franchise: Benefitting patients globally
Ophthalmology franchise: Benefitting patients globally Faricimab: Positive results in DME & nAMD; PDS: launch on track Faricimab Port delivery system (anti-VEGF/Ang-2 biMab) (PDS) • Ph III (ARCHWAY) data in nAMD show more than 98% of • Ph III (YOSEMITE & RHINE) results in DME positive with patients
Slide 36: Infectious diseases: SARS-CoV-2 development program
Infectious diseases: SARS-CoV-2 development program Positive read-outs for nAb cocktail – first shipments Casirivimab + imdevimab (nAb cocktail): • Ph II (Study 2067) in outpatient setting: Primary endpoint of viral load reduction met; FDA EUA granted on Nov 20; First governmental orders from US and
Slide 37: 2020: Key late-stage news flow
2020: Key late-stage news flow* Additional 2020 news flow: • Gavreto: US approval in RET fusion-positive mNSCLC • casirivimab/imdevimab: Positive Ph II results in outpatients; US EUA granted • Gavreto: US approval in metastatic RET+ thyroid cancer • Actemra: Positive Ph III (EMPACTA) in severe COVID
Slide 38: 2021: Key late-stage news flow
2021: Key late-stage news flow* Compound Indication Milestone Evrysdi SMA type 1/2/3 EU approval PDS ranibizumab nAMD (continuous delivery) US/EU filing; US approval faricimab DME/nAMD US/EU joint filing (DME+AMD) Regulatory casirivimab/imdevimab SARS-CoV-2 EU approval Venclexta + azacitidine 1L unf
Slide 39: Diagnostics Division
Diagnostics Division Thomas Schinecker CEO Roche Diagnostics
Slide 40: 2020: Diagnostics Division sales
2020: Diagnostics Division sales Strong growth driven by Molecular Diagnostics 2020 2019 Change in % CHFm CHFm CHF CER Diagnostics Division 13,791 12,950 6 14 Centralised and Point of Care Solutions 7,273 7,819 -7 -1 Molecular Diagnostics 3,760 2,109 78 90 Diabetes Care 1,670 1,918 -13 -5 Tissue Dia
Slide 41: 2020: Diagnostics Division regional sales
2020: Diagnostics Division regional sales Growth driven by COVID-19 testing Japan North America +5% +26% EMEA1 ~4% of divisional sales ~28% of divisional sales +19% ~40% of divisional sales Asia Pacific Latin America -3% +14% ~23% of divisional sales ~6% of divisional sales All growth rates at Const
Slide 42: 2020: Diagnostics Division highlights
2020: Diagnostics Division highlights Strong growth driven by COVID-19 testing YoY CER growth Centralised • Immunodiagnostics (-6%) and Point -1% • Clinical Chemistry (-11%) of Care Solutions • POC3 Immunodiagnostics (+667%) • Virology (+180%) Molecular 1 +90% • LightMix Systems (+189%) Diagnostics
Slide 43: 2020: Diagnostics Division core operating profit
2020: Diagnostics Division Very strong core operating profit growth of +50% 2020 2020 vs. 2019 CHFm % sales CER growth Sales 13,791 100 14% -26% Royalties & other op. inc. 61 0.4 -26% Cost of sales -6,497 -47.0 10% M&D -2,728 -19.8 0% R&D -1,556 -11.3 10% G&A -507 -3.7 3% Core operating profit 2,564
Slide 44: SARS-CoV-2 diagnostics portfolio
SARS-CoV-2 diagnostics portfolio1 Comprehensive portfolio of tests and digital solutions Clinical Labs Near Patient • TIB MOLBIOL LightMix® Modular SARS-CoV-2 Launched Molecular • cobas® SARS-CoV-2 & Influenza A/B Launched • cobas® SARS-CoV-2 Launched solutions • cobas® SARS-CoV-2 & Influenza A/B La
Slide 45: Investing CHFm >600 to increase supply chain capacities
Investing CHFm >600 to increase supply chain capacities Driving to unprecedented volume in record time! CONSUMABLES REAGENTS • 60 new manufacturing lines • 20 new manufacturing lines • 17 locations with 5 new partners • 4 major facility expansions • CHFm >600 investment • >1200 new employees • 8 new
Slide 46: Launch of Elecsys SARS-CoV-2 Antigen Test
Launch of Elecsys® SARS-CoV-2 Antigen Test in CE mark countries High performing test to detect SARS-CoV-2 Elecsys® In-solution double-antibody sandwich Phase 1 Ru • Test to detect active SARS-CoV-2 infections 9 min • Excellent performance: – Sensitivity 94.5% (n=200 positive samples1) Phase 2 Ru – S
Slide 47: FDA grants EUA for Elecsys Anti-SARS-CoV-2 S immunoassay
FDA grants EUA for Elecsys® Anti-SARS-CoV-2 S immunoassay In clinical studies with major vaccine developers Elecsys® In-solution double-antigen sandwich • FDA Emergency use authorization1 on December 2nd • Quantitative immunoassay detecting antibodies to the receptor binding domain (RBD) of the spik
Slide 48: Launch of cobas PIK3CA Mutation Test
Launch of cobas® PIK3CA Mutation Test (CE-IVD) Enables clinicians to make fast targeted treatment decisions PIK3CA pathways in cancer Extracellular Growth Factor Cell membrane Growth Factor Receptor • PCR test for detection of 17 PIK3CA mutations in advanced or metastatic (FGFR and EGFR family membe
Slide 49: End-to-end Digital Pathology solution with IVD image analysis
End-to-end Digital Pathology solution with IVD image analysis Powerful pipeline utilising latest advances in AI technology SCANNING PATHOLOGIST IMAGE WORKFLOW ANALYSIS VENTANA DP 200 NAVIFY Digital uPath Image Analysis Pathology Algorithms • Three next-generation CE-IVD algorithms launched in 2020 u
Slide 50: Outlook on 2021 new systems launches
Outlook on 2021 new systems launches Enabling comparable results in different size laboratories Throughput Low Medium High cobas® pure* cobas® pro cobas® pro (high throughput) SWA** solutions cobas® 5800* cobas® 6800 cobas® 8800 Molecular solutions * Currently in development and not commercially ava
Slide 51: Roche Diagnostics Investors Day 2021
Roche Diagnostics Investors Day 2021 Innovating Diagnostics, Shaping Healthcare, Changing lives 23rd March 2021, 14:00-16:00 CEST (virtual set up) Presenters: Thomas Schinecker, CEO Diagnostics Ann Costello, Global Head Roche Diagnostics Solutions Palani Kumaresan, Head of Research & Development Ben
Slide 52: Key launches 2020
Key launches 2020 Area Product Description Market1 Workflow cobas® prime Next generation pre-analytical platform to support cobas® 6800/8800 Systems CE Instruments/ Devices Diabetes Accu-Chek Solo Diabetes Integration of the Accu-Chek Guide test strip technology into the Accu-Chek CE Care Manager So
Slide 53: Key launches 2021
Key launches 2021 Area Product Description Market1 cobas® pure integrated solutions Low-to-medium volume SWA CE Core Lab cobas® pro integrated solutions New high throughput configurations of the cobas pro instrument CE Point of Care cobas® pulse Successor of Accu-Chek® Inform II CE Instruments cobas
Slide 54: Finance
Finance Alan Hippe Chief Financial Officer
Slide 55: 2020 results, Focus on Cash, Outlook
2020 results Focus on Cash Outlook 55
Slide 56: 2020: Highlights
2020: Highlights Business • Sales growth of +1%1 despite biosimilars impact of CHF -5.1bn2 • Core operating profit up +4%1 and Core EPS growth of +4%1 • Dividend3 in Swiss francs further increased Cash flow • Operating Free Cash Flow of CHF 14.8bn despite higher investments in in-licensing and highe
Slide 57: 2020: Successfully managing the transition in volatile environment
2020: Successfully managing the transition in volatile environment Compensated for biosimilar & COVID-19 Efficiency gains & investment into future Group Group Sales Core OP CHFm (CER) + 4,739 CHFm (CER) - 5,051 2 + 981 + 1,812 + 1,800 - 40 -868 - 803 - 5,919 23,460 23,460 61,396 62,015 - 968 22,478
Slide 58: 2020: Group performance
2020: Group performance Core operating profit up +4 & Core EPS growth of +4% 2020 2019 Change in % CHFm CHFm CHF CER Sales 58,323 61,466 -5 1 Core operating profit 21,536 22,479 -4 4 as % of sales 36.9 36.6 Core net income 17,378 18,062 -4 5 as % of sales 29.8 29.4 Core EPS (CHF) 19.16 20.16 -5 4 IF
Slide 59: 2020: Group sales
2020: Group sales CER sales increase of +1%, driven by Diagnostics and International, partly offset by a decrease in the US; Fx impact of -6%p -6% +1% +7% -6% +1% -5% Pharma Division Dia Division -2% +14% +14% +1,800 +620 -241 -1,689 +89 +661 -3,763 -3,143 PY: +62 11 United States Europe Intl. Chuga
Slide 60: 2020: Core EPS development
2020: Core EPS development Operations growth is main driver for Core EPS growth CHF +4.2% +4.9 p +0.3 p +0.9 p -1.1 p -0.1 p -0.7 p 21.20 20.35 FY 2019 Income Gainsfrom ROOI Gains equity securities Bond redemption Resolution tax disputes Other, mainly sales FY 2020 Other Gains equity Bond Resolution
Slide 61: 2020: Group operating performance
2020: Group operating performance Core operating profit growth ahead of sales growth 2020 2020 vs. 2019 CHFm abs. CER CER growth Sales 58,323 620 1% Royalties & other op. inc. 2,020 -175 -8% Cost of sales -14,567 1,015 -6% M&D -9,361 631 -6% R&D -12,153 -953 8% G&A -2,726 -157 6% Core operating prof
Slide 62: 2020: Royalties and other operating income
2020: Royalties and other operating income Lower income on product disposals, partially offset by higher other operating income from Venclexta profit share CHFm +70 -57 -27 2,285 -251 Royalties and other operating income decreased by -8% at CER 2,020 1 2 3 4 5 6 Royalty income Out-licensing Other op
Slide 63: Major transformation ongoing across the Group
Major transformation ongoing across the Group Example: Cost of Sales Cost of Sales 2019 2020 abs. CER % CER Pharma Division 10,180 8,070 +1,652 -16% • Manufacturing cost of goods sold and period costs: Product mix, productivity improvements, and lower Manufacturing cost 6,086 5,021 +787 -13% invento
Slide 64: 2020: Core operating profit and margin
2020: Core operating profit and margin 43.1% 43.3% 43.7% % of sales 36.1% 36.6% 36.9% +1.1%p¹ +1.2%p¹ +4%¹ CHFm 18.6% 22,479 21,536 0%¹ 15.9% 15.2% 20,505 21,015 18,942 19,477 +4.8%p¹ +50%¹ 2,046 1,966 2,564 2018 2019 2020 Roche Group Pharma Division Diagnostics Division 1 At CER=Constant Exchange R
Slide 65: 2020: Core net financial result
2020: Core net financial result Improvement driven by net loss on debt redemption in 2019 and lower interest expenses CHFm • Net financial expenses decreased by +34% at CER • Interest expenses1 decreased by +26% at CER -564 -903 +58 +182 +202 -87 -15 -1 Net interest Equity G/L on debt Interest 2019
Slide 66: 2020: Group Core tax rate
2020: Group Core tax rate Tax rate relatively stable excluding resolution of several tax disputes % +0.2p -1.5p +2.1p 18.4 18.6 17.1 16.3 -3,880 2019 2019 2020 2020 As reported Resolution of Before Tax development Before Resolution of As reported Tax Disputes Resolution of (excluding Resolution of T
Slide 67: 2020: Non-core and IFRS income
2020: Non-core and IFRS income Total non-core operating items decreasing due to lower IA impairments and Legal & Environmental income 2019 2020 Change in % CHFm CHFm CHFm CHF CER Core operating profit 22,479 21,536 -943 -4 +4 Global restructuring plans -1,206 -909 297 Amortisation of intangible asse
Slide 68: 2020 results, Focus on Cash, Outlook
2020 results Focus on Cash Outlook 68
Slide 69: 2020: Operating Free Cash Flow
2020: Operating Free Cash Flow OFCF down by -21% driven by Net Working Capital movement and higher investments in Intangible Assets CHFm -74 -2,307 -216 -1,838 -1,671 20,921 OFCF lower by -21% / -4,435m at CER 14,815 2019 OP, net of cash NWC Investments Investments Foreign 2020 adjustments movement
Slide 70: 2020: Group net debt lower vs. YE 2019
2020: Group net debt lower vs. YE 2019 Free Cash Flow CHF 10.9bn CHFbn vs. 16.8bn in 2019 -3.9 -10.3 +14.8 [PY: +20.9] -2.5 -1.9 Taxes -3.2 Dividends paid -8.0 Treasury -0.7 Trans. own eq. instr. -2.1 M&A & All. trans. -1.2 Curr. Transl. & Other +1.0 Net debt Operating Non-Operating Dividends, M&A N
Slide 71: Balance sheet 31 December 2020
Balance sheet 31 December 2020 Equity ratio at 46% (31 Dec 2019: 43%) % change in CER % change in CER CHFbn vs 31 Dec 2019 vs 31 Dec 2019 83.1 86.1 83.1 86.1 +9% +9% Cash and 12.3 marketable 11.9 +7% 14% 25.4 securities 14% Current 24.1 +12% 29% 29% 19.4 20.6 +13% liabilities Other 23% 24% current a
Slide 72: 2020 results, Focus on Cash, Outlook
2020 results Focus on Cash Outlook 72
Slide 73: High currency impact in 2020
High currency impact in 2020 CHF / USD Average -3% -3% -4% -5% YTD 2019 In 2020 impact1 is (%p): 1.00 1.00 0.99 1.00 Q1 HY Sep FY 0.95 0.94 0.97 0.97 YTD Average YTD 2020 Sales -5 -5 -6 -6 0.97 0.97 0.96 0.97 0.97 0.95 0.94 0.91 0.91 0.91 0.91 0.89 Core operating Monthly avg fx rates 2020 -7 -8 prof
Slide 74: 2020: Core EPS
2020: Core EPS Core EPS 2020 of CHF 19.35 is basis for Core EPS outlook 2021 at CER CHF +0.19 19.16 19.35 Core EPS 2020 as 2020 foreign Core EPS 2020 basis reported exchange losses: for Outlook Core EPS Core EPS impact growth 2021 at CER CER = Constant Exchange Rates 74
Slide 75: 2021 outlook: Further growing top and bottom line
2021 outlook Further growing top and bottom line Group sales growth1 • Low- to mid-single digit Core EPS growth1 • Broadly in line with sales growth Dividend outlook • Further increase dividend in Swiss francs 1 At Constant Exchange Rates (CER); based on the current assessment of the COVID-19 impact
Slide 76: Roche
Slide 77: Changes to the development pipeline
Changes to the development pipeline Q4 2020 update New to phase I New to phase II New to phase III New to registration 7 NMEs: 2 NMEs: 3 NMEs: 1 NME: RG6006 Abx MCP - bacterial infections RG6359 SPK-3006 - Pompe disease RG7845 fenebrutinib – PPMS RG6321 PDS with ranibizumab - wAMD RG6007 HLA-A2-WT1
Slide 78: Roche Group development pipeline
Roche Group development pipeline Phase I (49 NMEs + 14 AIs) Phase II (22 NMEs + 12 AIs) RG6007 HLA-A2-WT1 x CD3 AML CHU FIXa x FX hemophilia giredestrant (SERD) neoadjuvant ER+ BC RG6171 RG6026 glofitamab monotherapy and combos heme tumors CHU glypican-3 x CD3 solid tumors giredestrant (SERD) 2/3L E
Slide 79: Roche Group development pipeline
Roche Group development pipeline Phase III (14 NMEs + 34 AIs) Registration (4 NMEs + 7 AIs) RG6013 Hemlibra mild to moderate hemophilia A RG6268 Rozlytrek ROS1+ 1L NSCLC Gavreto (pralsetinib) 1 RET+ NSCLC RG6396 RG6026** glofitamab + chemo 2L+ DLBCL Venclexta r/r MM t(11:14) Gavreto (pralsetinib) 3
Slide 80: NME submissions and their additional indications
NME submissions and their additional indications Projects in phase II and III TLR7 ago (3) glofitamab + chemo RG7907+ RG6026 + CpAM (2) 2L DLBCL RG7854 HBV tiragolumab + ralmitaront FGFR1 x KLB MAb RG6058 Tecentriq (T) RG7906 RG7992 schizophrenia NASH 1L PD-L1+ cervical ca microdystrophin rhPTX-2 ti
Slide 81: AI submissions for existing products
AI submissions for existing products Projects in phase II and III New Molecular Entity (NME) Immunology Neuroscience Additional Indication (AI) Infectious Diseases Ophthalmology Oncology / Hematology Metabolism Other Tecentriq + Avastin RG7446 HCC adj Tecentriq RG7446 SC NSCLC Xolair ✓ Tecentriq RG3
Slide 82: Major pending approvals 2020-YTD 2021
Major pending approvals 2020-YTD 2021 US EU China Japan-Chugai Esbriet Enspryng (satralizumab) Evrysdi (risdiplam) Polivy RG6062 UILD RG6168 NMOSD RG7916 SMA RG7596 r/r DLBCL Filed Nov 2020 Filed Aug 2019 Filed March 2020 Filed June 2020 Alecensa (BFAST) Tecentriq Enspryng (satralizumab) Evrysdi (ri
Slide 83: Major granted approvals 2020 and YTD 2021
Major granted approvals 2020 and YTD 2021 US EU China Japan-Chugai Venclexta+Gazyva Xofluza Polivy Kadcyla Rozlytrek (entrectinib) RG7601 1L CLL RG6152 post exposure prophylaxis RG7596 r/r DLBCL RG3502 HER2+ eBC RG6268 ROS1+ NSCLC Mar 2020 Nov 2020 January 2020 Jan 2020 Feb 2020 Tecentriq+Avastin ca
Slide 84: Doing now what patients need next
Doing now what patients need next